European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
Percutaneous nephrostomy in the management of advanced and terminal-stage gynecologic malignancies: outcome and complications
V. Plesinac-Karapandzic1,*, D. Masulovic2, B. Markovic2, A. Djuric-Stefanovic2, S. Plesinac3, D. Vucicevic4, Z. Milovanovic1, Z. Milosevic1
1 Institute of Oncology and Radiology of Serbia, Belgrade
2 Institute of Radiology, Clinical Center of Serbia, Belgrade
3 Institute of Gynecology and Obstetrics, Clinical Center of Serbia, Belgrade
4 Institute of Pathology, Medical Faculty Pristina, Kosovska Mitrovica (Serbia)
Eur. J. Gynaecol. Oncol. 2010, 31(6), 645–650;
Published: 10 December 2010
Purpose: The goal of the study was to evaluate the outcome and complications after percutaneous nephrostomy (PCN) insertion in advanced and terminal-stage gynecological malignancies with ureteral obstruction (UO). Materials and Methods: We analyzed data of 117 patients with UO due to gynecological malignancies, who had undergone PCN between 1996.and 2006. Cervical cancer was evidenced in 108 patients, uterine carcinoma in six and ovarian cancer in three patients. Eighty-nine had UO at the initial manifestation of the disease, 22 had persistent or recurrent cancer, and six were disease-free after initial therapy. Oliguria was observed in 22.2% and creatine elevation in 79.5%. Mean follow-up was 11.43 months (range 0-112). Results: The median age was 51 years (range 28-85). Bilateral nephrostomy was performed in 36.7% and unilateral in 63.3%. Renal function normalization occurred in 24.8%. Overall two-year survival (OS) was 16.8%. Higher OS occurred in patients without initial azotemia versus those with azotemia (26.8% vs 13.9%). Median survival time for all the patients was seven months, eight in primary cases versus six in recurrent ones, and eight months in patients after initial therapy. Complications appeared in 53.85%. Most frequent were the loss of the nephrostomy catheter in 37.61% and urinary tract infections in 19.6%. Conclusion: Improvement of renal function after PCN can be of clinical benefit in patients who might be cured or for prolonged palliative care. Azotemia seems to be poor prognostic sign.